1. Hatlebakk JG, Katz PO, Camacho-Lobato J, et al. Proton pump inhibitors: better acid supression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14(10): 1267–1272.
2. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17(1): 22–37.
3. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practicing physicians. Best Pract Res Clin Gastroenterol 2001; 15(3): 355–370.
4. Rackoff A, Agrawal A, Hilla A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18(6): 370–373.
5. Martínek J, Lukáš M. Inhibitory protonové pumpy – up to date. Gastroent Hepatol 2011; 65(6): 331–342.
6. Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 2008; 28(5): 263–279.
7. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 2001; 13 Suppl. 1: S35–41.
8. Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H, K – ATP-ase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272(36): 22438–22446.
9. Horn J. Review article: understanding the pharnacodynamic and pharmacokinetic differences between proton pump inhibitors – focus on pKa and metabolism. Aliment Pharmacol Ther 2006; 2(2): 340–350.
10. Morelli G, Chen H, Rossiter G, et al. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther 2011; 33(7): 845–854.
11. Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human P450 activities. Drug Metab Dispos 2004; 32(8): 821–827.
12. Friedlander EA, Pallentino J, Miller SK, et al. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease. J Am Acad Nurse Pract 2010; 22(12): 674–683.
13. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency on proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65(1): 19–31.
14. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44(7): 297–302.
15. Katz PO, Tutuian R. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol 2001; 15(3): 371–384.
16. Pace F, Sonnenberg A, Bianchi Porro G. The lessons learned from randomized clinical trials of GERD. Dig Liver Dis 2007; 39(11): 993–1000.
17. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesopohageal reflux disease: a metaanalysis. Gastroenterology 1997; 112(6): 1798–1810.
18. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastroesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18(6): 559–568.
19. Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16(3): 479–485.
20. Maiti R, Jaida J, Israel PL, et al. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011; 2(3): 150–157.
21. Altman KW, Prufer N, Vaezi MF. A review of clinical practice guidelines for reflux disease: toward creating a clinical protocol for the otolaryngologist. Laryngoscope 2011; 121(4): 717–723.
22. McNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36(5): 414–425.
23. Tang HL, Li Y, Hu YF, et al. Effects of CYP2C19 Loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. PLoS One 2013; 8(4):e62162. doi: 10.1371/journal.pone.0062162.
24. Tamura T, Kurata M, Inoue S, et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping. Nagoya J Med Sci 2011; 73(1-2): 25–31.
25. Selgrad M, Bornschein J, Malfertheiner P, et al. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther 2011; 9(8): 581–588.
26. Tielemans MM, Eikendal T, Jansen JB, et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010; 33(6): 443–453.
27. Iwamoto J, Saito Y, Honda A, et al. Clinical features of gastroduodenal injury associated with long-term low dose aspirin therapy. World J Gastroenterol 2013; 19(11): 1673–1682.
28. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin-what´s the risk? Aliment Pharmacol Ther 2006; 24(6): 897–908.
29. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104(3): 728–738.
30. Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol 2012; 165(1): 67–74.
31. Vakil N. Proton pump inhibitors for dyspepsia. Dig Dis 2008; 26(3): 215–217.
32. Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis 2008; 26(3): 225–230.
33. Veldhuyzen Van Zante SJ, Chiba N, Armstrong B, et al. A randomized trial comparing omeprazole, ranitidine, cisapride or placebo in Helicobacter pylori negative, primary care patiens with dyspepsia: The CADET-HN study. Am J Gastroenterol 2005; 100(7): 1477–1488.
34. Thomson AB, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16(19): 2323–2330.
35. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010; 24(2): 193–201.
36. Lamberts R, Brunner G, Solcia E, et al. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205–213
37. Malfertheiner P, Megraud F, O´Morain C, et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florance consensus report. Gut 2012; 61(5): 646–664.
38. Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morfology under prolonged acid inhibition therapy: results of 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36(10): 959–971.
39. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24(9): 1341–1348.
40. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124(6): 519–526.
41. Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337(7662): a425.
42. The U.S. Food and Drug Administration. FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs)[online]. 2011-02-03 [cit. 2013-05-10]. Dostupný na: www.fda.gov/Drugs/DrugSafety/ucm245011.htm
43. Sultan N, Nazareno J, Gregor J, et al. Association between proton pump inhibitors and respiratory infections: A systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008; 22(9): 761–766.
44. Eom CH-S, Jeon ChY, Lim J-W, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183(3): 310–319.
45. Giuliano C, Wilhem SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5(3): 337–344.
46. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54(3): 243–245.
47. Deshpande A, Pant Ch, Pasupuleti V, et al. Association between proton pump inhibitor therapy and clostridium difficile in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10(3): 225–233.
48. Ogawa R, Echizen H. Drug-drug interactions profiles of proton pump inhibitors. Clin Pharmacokinet 2010; 49(8): 509–533.
49. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors – where do we stand in 2012? World J Gastroenterol 2012; 18(18): 2161–2171.
50. Chen J, Yuan YC, Leontiadis GI, et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46(2): 93–114.
51. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363(20): 1909–1917.
52. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. J Am Coll Cardiol 2010; 56(2): 134–143.
53. Uotani T, Sugimoto M, Nishino M, et al. Ability od rabeprazole to prevent gastrin mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19. Clin Gastroenterol Hepatol 2012; 10(8): 879–885.
54. El-Halabi MM, Zgheib N, Mansour NM, et al. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the anti-platelet action of clopidogrel. J Cardiovasc Pharmacol 2013 Mar 7. [Epub ahead of print].
55. DeVault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 2009; 6: 524–532.
56. Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010; 12: 437–447.